Switching patients between Pristiq® and other antidepressants
Discontinuation symptoms have been reported when switching patients from other antidepressants, including venlafaxine to desvenlafaxine. Tapering of the initial antidepressant followed by a washout period may be necessary to minimise discontinuation symptoms and the possibility of drug-drug interactions from a pharmacokinetic or pharmacodynamic perspective.1
Pfizer does not have any specific recommendations with regards to switching patients between antidepressants, including to/from Pristiq.1
You may wish to refer to tertiary references to assist in your clinical decision. For your reference, an antidepressant changeover guide from the Australian Medicines Handbook2 has been provided below.
Antidepressant Changeover Guide2
© Australian Medicines Handbook 2016
|Category A changeover|
|fluoxetine, phenelzine, tranylcypromine, vortioxetine||drug (or metabolites) with long half-life or persistent effects|
|Category B changeover|
|TCAs, SSRIs (except fluoxetine), mianserin, mirtazapine||drug (or metabolites) with intermediate half-life of 24-48 hours|
|Category C changeover|
|agomelatine, moclobemide, reboxetine, SNRIs||drug (or metabolites) with short half-life of <18 hours|
|* interval before starting next antidepressant may differ from that recommended by other sources, eg product information|
- Pristiq®(desvenlafaxine) Product Information
- Antidepressant changeover guide © Australian Medicines Handbook Pty Ltd 2016 (last modified by AMH January 2016)
Use of Pristiq® during pregnancy & lactation
Pregnancy Category B2; the safety of Pristiq in human pregnancy has not been established. Only administer Pristiq to pregnant women if the expected benefits outweigh any possible risk. If Pristiq is used until, or shortly before birth, discontinuation effects in the newborn should be considered.
Desvenlafaxine (O-desmethylvenlafaxine) is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from desvenlafaxine, a decision should be made whether or not to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Only administer Pristiq to breastfeeding women if the expected benefits outweigh any possible risk.
Presence of Pristiq® tablet in the stool
Patients receiving Pristiq may notice an inert matrix tablet passing in the stool or via colostomy. Patients should be informed that the active medication has already been absorbed by the time the patient sees the inert matrix tablet.
Halving or crushing Pristiq® tablets
Pristiq is formulated as an extended-release tablet for once-a-day oral administration. Tablets must be swallowed whole with fluid and not divided, crushed, chewed or dissolved.
Due to the complex nature of the carefully controlled release of active drug from the tablet, splitting, crushing, or placing the tablet in solution alters the exposed surface area of the tablet and disrupts the extended release mechanism. Active drug is physically constrained in a rate-controlling polymer (hypromellose) and the tablet surface area/tablet volume ratio must not be disrupted to prevent alteration of the release-rate of active drug. Any type of physical alteration to the tablet may result in various types of untoward responses including erratic absorption of dose, failure to achieve adequate plasma concentrations and a rapid release of excessive amount of drug that may result in acute precipitation of adverse effects.
Tips and Tricks
Contact Pfizer Medical Information
Monday to Friday 9am – 5pm EST